Development of Recombinant Anti-TLR2 Antibodies and PLGA Nanoparticle-based Gene Therapy for the Treatment of Neuropathic Pain
Lee, S.; Jeon, J.; Lee, H.; Barcelona, E. E.; Hong, J.; Lee, S. J.
Show abstract
Neuroinflammation is a key contributor to neuropathic pain, with microglial Toll-like receptor 2 (TLR2) playing a central role in initiating and sustaining proinflammatory responses. However, existing TLR2-targeting antibody therapies are limited by poor delivery to the central nervous system and short-lived efficacy. We developed a non-viral gene therapy strategy using biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) to deliver recombinant anti-TLR2 antibody genes. High-affinity nanobody and single-chain variable fragment candidates were selected through phage display screening and shown to suppress TLR2-dependent signaling both in vitro and in vivo. In mouse models of neuropathic pain, a single intrathecal administration of PLGA NP-encapsulated antibody genes produced robust and sustained analgesia, accompanied by reduced glial activation and proinflammatory cytokine expression. These findings demonstrate a modular NP-based platform for sustained antibody expression in the central nervous system and establish its potential for the treatment of chronic pain driven by innate immune activation.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Massively parallel screening of TIR-derived peptides reveals vast TLR-targeting immunomodulatory peptides 96%
- TSHR-targeting nucleic acid aptamer treats Graves' ophthalmopathy via novel allosteric inhibition 94%
- Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics 93%
Similar papers in this journal
- A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses 94%
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy 94%
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 94%
Similar papers in this journal
- High throughput functional screening for next generation cancer immunotherapy using droplet-based microfluidics 94%
- A claudin5-binding peptide enhances the permeability of the blood-brain-barrier 93%
- In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles 93%
Similar papers in this journal
- Langerhans Cell-targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response 93%
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 93%
- Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer 93%
Similar papers in this journal
- Immunofilaments Provide a Nanoscale Platform for In Vivo T Cell Expansion and Cancer Immunotherapy 94%
- Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing 94%
- SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity Through B Cell Antigen Presentation 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.